Experimental vax could reverse Parkinson's

An experimental vaccine being studied at the University of Nebraska Medical Center successfully spurred the development of dopamine-producing nerve cells, reversing the disease in mice. And after more than a decade of work on the vaccine, the scientists are anxious to determine if the same vaccine strategy would also work in humans. Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.